Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Sponsor: Array BioPharma
Terminated
Study was withdrawn due to scientific and business considerations.
This PHASE1/PHASE2 trial investigates Locally Advanced Metastatic BRAF Mutant Melanoma and is currently terminated or withdrawn. Array BioPharma leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Array BioPharma
For direct contact, visit the study record on ClinicalTrials.gov .